Xenon Pharmaceuticals (XENE) Fundamentals 2026 — Revenue Analysis | SniperIQ
Xenon Pharmaceuticals (XENE) is a CA-listed Healthcare company in Biotechnology with a market capitalization of $5.2B, trading at $66.31 on the NASDAQ. This SniperIQ fundamentals page covers Xenon Pharmaceuticals's valuation, profitability (net margin 0.0%), revenue ($8M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Xenon Pharmaceuticals's market cap?
Xenon Pharmaceuticals (XENE) has a market capitalization of approximately $5.2B, trading at $66.31 on the NASDAQ. Market cap moves with the live share price.
What is Xenon Pharmaceuticals's P/E ratio?
Xenon Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 4.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Xenon Pharmaceuticals?
Xenon Pharmaceuticals runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Xenon Pharmaceuticals generate?
Xenon Pharmaceuticals reported revenue of $8M for fiscal year 2025, with net income of -